Patent Application: Detecting Pancreatic Cancer

ChangeBridge: Patent Apps - Peptides (C07K)

Published July 24th, 2025

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260085360A1) detailing methods for detecting pancreatic cancer. The application describes a method involving measuring CA19-9 levels alongside other markers like OPN, MIA, and CEACAM-1 in a subject's sample.

View original document View source feed page

What changed

This document is a published patent application from the USPTO, not a regulatory rule or guidance. It describes compositions and methods for detecting pancreatic cancer by measuring levels of CA19-9 polysaccharide and specific polynucleotide or polypeptide markers (OPN, MIA, CEACAM-1, MIC-1, SPON1, HSP27, POSTN, and LGALS3BP) relative to a reference. An increase in both CA19-9 and at least one other marker indicates the presence of pancreatic cancer.

As a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it may inform future research and development in diagnostic tools for pancreatic cancer, potentially impacting companies in the biotechnology and medical device sectors. Compliance officers should note this as a development in diagnostic technology rather than an immediate regulatory requirement.

Source document (simplified)

← USPTO Patent Applications

COMPOSITIONS AND METHODS FOR DETECTING PANCREATIC CANCER

Application US20260085360A1 Kind: A1 Mar 26, 2026

Inventors

Jin Song, Zhen Zhang, Daniel Wan-Yui Chan

Abstract

Provided herein are methods of detecting pancreatic cancer in a subject, the method comprising measuring in a sample from the subject a level of CA19-9 polysaccharide relative to a reference, and a level of a polynucleotide or polypeptide of at least one marker selected from the group consisting of: OPN, MIA, CEACAM-1, MIC-1, SPON1, HSP27, POSTN, and LGALS3BP relative to a reference, wherein an increased level of the CA19-9 polysaccharide relative to a reference and an increased level of the polynucleotide or polypeptide relative to a reference indicates presence of pancreatic cancer in the subject.